ArticleEuropean journal of nuclear medicine and molecular imaging2024
Non-invasive visualization of liver fibrosis with [
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04605939 (Clinical Application of Fibroblast Activation Protein PET/MRI for Diagnosis and Staging in Liver Fibrosis), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Application of Fibroblast Activation Protein PET/MRI for Diagnosis and Staging in Liver Fibrosis
Who cites it
14 citing papers in PubMed.
- Assessment of liver fibrosis and tumor burden in hepatocellular carcinoma using [European journal of nuclear medicine and molecular imaging · 2026Trial
- Molecular PET imaging of integrin αvβ6 reveals biliary and fibrotic changes in preclinical MASH.Biomarker research · 2026Article
- FAP-targeted [European journal of nuclear medicine and molecular imaging · 2026Article
- [Scientific reports · 2026Article
- Application of 18F-FAPI PET/CT in Deep Infiltrating Endometriosis.Clinical case reports · 2026Article
- The diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma: a head-to-head comparison with 18 F-FDG PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
- A pilot human-based study ofScientific reports · 2026Article
- Performance of [European journal of nuclear medicine and molecular imaging · 2026Article
- FAPI TracerPharmaceuticals (Basel, Switzerland) · 2025Article
- Molecular Imaging Probes for Early Detection and Staging of Liver Fibrosis.Chemical & biomedical imaging · 2025Review
- PET imaging of platelet derived growth factor receptor β in lung fibrosis.EJNMMI radiopharmacy and chemistry · 2025Article
- Efficacy of [Annals of nuclear medicine · 2025Article
- FAPi PET/CT Imaging to Identify Fibrosis in Immune-Mediated Inflammatory Diseases.Biomedicines · 2025Review
- CombinedFrontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
purposeThe reversibility of early liver fibrosis highlights the need for improved early detection and monitoring techniques. Fibroblast activation protein (FAP) is a promising theranostics target significantly upregulated during fibrosis. This preclinical and preliminary clinical study investigated a FAP-targeted probe, gallium-68-labeled FAP inhibitor 04 ([
methodsThe preclinical study employed [
results[
conclusion[
trial registrationNCT04605939. Registered October 25, 2020, https://clinicaltrials.gov/study/NCT04605939.
Indexed as
Identifiers
38850311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.